The genesis of Micro Group is from Micro Labs, the nucleus. The flag-ship division is the face of Micro Group in the Indian Pharmaceutical arena, through, mega brands such as Dolo – 650, Anxit, Silybon, Gramocef – CV, Ebast and Levobact in their respective categories.

Dolo is ‘The top league’ brand of this division. The brand has surpassed all major players with a ranking of 208 as per retail audit across India and has gained 12th rank in terms of prescription audit (all India) by IMS. According to IMS report for May 2010, Dolo – 650 is the No. 1 prescribed brand in South India.

The DNA of Micro Labs is the double helix, comprising of two parallel strands which include the Doctors & retailers, and the patients acting as the connecting strands.

The division draws its strength from years of proximity with doctors across the country, across various specialties that include Physicians, Surgeons, Orthopedic, ENT specialists, Gynecologists, Pediatricians, Chest specialists and General Practitioners. The division thus reaches out to all segments of customers, right from general practitioners to super specialists. The field force of Micro Labs is renowned for meaningful “Doctor – Dialogues” resulting in “Brand – Building”

The thrust at doctor level is equally complemented by retail thrust. The division is known for its “Retailer–Relationship”. The wide – spread availability of the division’s brands across a large number of chemists in India stands testimony to the division’s retail penetration.

The success of Micro Labs derives from the competent and effective field force, which has proven their mettle in handling diverse therapy areas such as anti – infective, pain management, gastroenterological, anxiolytics, anti – depressants, nutraceuticals and anti-allergies.

Even with the advent of newer and newer molecules, there is still a need for long lasting look at the way Infections, Pediatric diseases; Gynaecological therapeutic approaches and Allergies are treated in the Country.

Keeping this broader objective in mind, and to serve the business need, Micro Nova division was launched in the year 1997.

One of the major working principles of this division is studying the market dynamics, based on which projections for top line contributors are arrived at. The needs of the Doctor are duly addressed in the management of disease conditions through effective planning of newer molecule introductions; where possible, dose formulations are titrated to provide the right Clinical options to the Medical fraternity.

Nova is diversified to meet the varying clinical needs of the Doctors as well as to comply with the varied needs of patients.

Nova as a Division offers a wide therapeutic basket in the form of Antibiotics, Analgesic-Antipyretics, Haematinics, Nutritionals, Neurotonics, Progesterone preparations, Antihistamines, Antiulcerants and Cough preparations.

The division offers major Antibiotic brands like Microcef, Bicef, Azilide and Analgesic, Antipyretic range like Dolopar, having a turnover of Rs.1 Crore each per month and each of these is ranked among the top 10 brands in their respective therapy segments.

With a field force of around 400 people, Nova is emerging as a fast growing division of Micro Labs.

Nova Aims

“To grow as the most Efficient, Professionally competent, Systems & Value driven and Profitable Organization whom the Doctor fraternity would like to be associated with and the sales force will be delighted to work for, keeping mutual progress in mind.”

Vision is an Ophthalmic division of Micro Labs Ltd. Inception of Vision was in the year 1999 with the mission to manufacture and market high quality eye care products at an affordable price in India and all over the world.

Vision made its mark in the very first year of its launch with the introduction of the breakthrough steroid with anti-infective combination, Microflox DX (Ciprofloxacin + Dexamethasone) which revolutionized post-operative care bringing steroid with Fluoroquinolone for the first time ever in the Ophthalmic market.

The R & D of Micro Labs indigenously developed the first Indian formulation of Fluorometholone, Flurisone and this pioneering effort opened gates for molecules & formulations available in the global market to be developed in India.

Since then Vision has pioneered the introduction of a plethora of Ophthalmic products across therapy areas of Ophthalmology like, Lubrex, the fist Indian formulation of Carboxymethylcellulose for the management of Dry Eyes, Misopt, the first Indian combination of Dorzolamide + Timolol for the management of glaucoma and Levobact, the first formulation of Levofloxacin eye drop for the treatment of ocular infections in pediatric patients maintaining a high level of safety alongside. These pioneering introductions provided the Ophthalmologist of the country to provide better eye care to Indian patients.

The meteoric rise of Vision in the Ophthalmic arena caught the attention of global Ophthalmic players to partner and market their research products in India. A historical and strategic partnership emerged in 2005 when LG Life Sciences, South Korea expressed their interest to market their Visco-elastic, LG-Hyal 2000 Injections in India using the highly dedicated and disciplined marketing team of Vision.

The setting up of State-of-Art dedicated Ophthalmic manufacturing facility in the year 2006 by Micro Labs was a landmark achievement. The facility meets highest quality and regulatory standards of USFDA & MHRA (UK). Equipped with world class high speed machines, the facility stands for dose accuracy and product quality. The untiring efforts of the organization to excel in providing quality eye care products from the facility has led to the facility winning Indian Drug Manufactures Award (IDMA) consecutively from 2007 to 2011.

Vision today markets over 30 Ophthalmic products across therapy areas in Ophthalmology with a turn-over of over Rs.50 Crores.

In the recent years Vision has taken steps in bringing technological advancement in its products with the introduction of preservative free eye ointments for the first time in India in world class packaging. The R & D of Micro Labs has further enhanced the image of the organization by providing the first self preserved anti-glaucoma medication, Travo-Z (Travoprost) to the Indian Ophthalmic market.

MHC stands for Micro Healthcare, a division which develops new competencies in marketing products that are used to treat Pain and Gastro therapies. This division was formed in the year 2006 and made a profit of 11 Crores.

MHC has developed a high perception in the minds of specialists by providing quality products and services.

MHC believes in customer satisfaction by providing branded quality products at affordable prices. MHC is committed to ensure consistent growth in covered market. This division is dynamic and flexible to grow with changing market trends.

MHC caters products to various specialties like Orthopedics, General Surgeons, Physicians, Gastro, General Practitioners with a range of products in Anti – arthritis, pain management and Gastro Intestinal disease management.

Major brands of this division are Bonmin, Rabiros, Spasmopriv, Metadoxil, Microcid, Tolpa-D. Other brands (Ortho) include Tolsafe, Zornica plus, Ultram, Winflam, Erofica, Ostogard. Progit, Cefglobe, Osmitol are for Gastro segment.

The division’s profit has reached Rs. 24 Crores in the year 2009 with a CAGR of 27.4%.

Healthcare is determined to outgrow covered market consistently.

Foresee is a super-specialty arm of Micro Labs Ltd that was launched in June 2007. This division was mainly started with an aim to expand its land mark in the field of nephrology. The division has been launched with a vision of being rated as top most discussed or sought after company in the field of Nephrology.

Foresee division offers a comprehensive range of products that include dialysis range, transplant range and critical care range of products, to cater to the nephrology segment. Foresee division currently markets brands that include: Eposis, Microfer, Lanthonate, Seegraf, Mycophen and Seebind.

This division focuses on leveraging with Brands re positioning and aggressive strategies to offer a complete basket of nephrology portfolio to doctors thereby increasing the business prospects. The division’s strategy is devised to add scientific value to its esteemed Clinicians & prove itself as a dependable partner in the field of nephrology. Foresee strongly believes– “The aim of business in not just to create but keep a customer”.

Foresee’s strong asset is its highly enthusiastic team which is equipped with new updates on nephrology & developments in the therapy segment, which is helping in developing & acquiring the business across the country.

Foresee division currently registers a turnover of Rs.15 Crore plus and aims to achieve more than Rs.50 Crore by 2014 -15.

SYNAPSE is named after an anatomical entity in the nervous system, a place between two neurons where both normal and abnormal mental activities take place in a human being.

SYNAPSE was the brain child of Micro Labs, CMD, Mr. Dilip Surana, and also our beloved founder Mr. G. C. Surana who strongly felt the need for an exclusive and dedicated CNS (Central Nervous System) outfit from Micro to focus exclusively on CNS product portfolio and to have a reasonably good presence in that elite branch of medicine. They also wanted to reinforce the commitment Micro had towards mental health care.

Few CNS products were already marketed by 2 – 3 divisions of Micro and to put all of them in one basket and have a greater concentration was the strategic approach and thus SYNAPSE took birth in April 1997.

With a humble beginning of 14 lakh, SYNAPSE grew from strength to strength from year after year to reach 2 Crore mark (per month) in 2002 with all India operations and Nepal & Sri Lanka. Currently SYNAPSE is hitting a target of 3.5 Crore per month and growing rapidly strong. SYNAPSE is ranked among top 10 major players in CNS segment.

This was possible only due to the sheer focus and building up the core customer relationship in the CNS segment ably anchored by the strong leadership which was effectively carried out in the field by the dedicated and dynamic team of SYNAPSE.

SYNAPSE caters to neurologists, psychiatrists with it’s elite CNS specialties and also covers selected customers in physician, diabetology and GP segments.

The major products of SYNAPSE are, PARKIN range, OLAN, RISPOND, PETRIL, ZOTRAL, FLURAZ, DORMIN, VERISIDEP, NEURICA-M, VALPRID CR and many more.

Synapse – Where we value our relationship, of course with our core and valued customers.

Gratia is a specialty division of Micro Labs exclusively dedicated to dermatology. This division was launched in the year 2007 with a team of 145 well trained executives. Gratia has a robust product range catering to General dermatology, Dermatology, Cosmetology and tricology.

The name Gratia is a Latin word and has several positive connotations all related to skin, its beauty and elegance. The Gratia logo represents its strong commitment to dermatology reflecting freedom from various dermatological problems and the nine petals represent Micro Labs. Skin is the largest organ in the body that covers and protects all other. It is in this context that Gratia product range comes very handy in offering the required cover and protection to the skin.

Leading dermatologists have reposed their trust and faith in Gratia’s product range, with no surprises; two of our products have already become brand leaders in their respective market – Viz Calosoft and Kojivit in a short span of time. Gratia firmly believes in scientific and professional approach. The highly acclaimed quality of Gratia products reflects its corporate theme ‘Dermatology our obsession.’

While Gratia is steadily improving its ranking in the covered market, it will not be satisfied till such time it becomes a very strong force to reckon with in the field of dermatology, cosmetology and tricology.

“The woods are lovely, dark and deep. But We have promises to keep, and miles to go before We sleep.”

Diabetes Task Force (DTF) division of Micro Labs Ltd was launched in 2005. With rapid increase of incidences of Type 2 diabetes in India, the country is already tagged as the diabetes capital of the world. The aim of this specialty division is to provide quality diabetes care.

The platforms on which the division is built are:

•  Scientific promotion : - Associated with all major bodies of diabetes research
•  Diabetes education : - Through a series of publications released on T2DM.
•  Patient education : - Organizing patient forum

The division, today, is ranked No 7 in OHA segment by IMS. Besides being present in all the molecule segments, Micro – DTF proudly owns some of the top brands such as Tripride, No 2 in triple combination segment & Dibizide – M, No 2 in the Glipizide and Metformin combination segment. The other prominent brands of the division are Diapride, Diapride M1 & M2, Melmet SR, Pregator,  Meconerv Plus and Melcovit Gold.

DTF recently launched Telrose (Telmisartan 40mg + Rosuvastatin 10mg) for the first time in India. We believe the new launch will cater to the ever increasing needs in diabetes care. 

EROS stands for Ethical, Reliable, Outstanding and Safe Medicines. It was formed in the year 1956, by Mr. P.S. Nayak. Eros was the first Indian pharma company to be accredited by ISO 9001 certification.

Prior to acquisition by Micro Labs, Eros operations were confined mainly to South India. The company was taken over by Micro Labs in 2002. Subsequently, it started to spread its wings all over India and now has its operations across the country.

After merging with Micro Labs, Eros has grown formidably. The turnover has grown from 11.5 Cr to 50 Cr in a short span of time. It is the sheer 'Discipline' 'Dedication' Determination and ‘Commitment’ of EROS TEAM across India who has taken up the challenge and become successful in this journey so far.

EROS caters products to various segments like Consultant Physicians, Chest Physicians, Family Physicians, Orthopedics, General Surgeons, Pediatricians, ENT, Dentists and Gynecologists with a range of Anti – Infective, Analgesic, Pain management, Anti allergic, Neutraceutical and Stomatologicals.

Our other major brands include: Rite-O-Cef, Erox, Divon, Montral, Etorica, Erophylline, Nitra Gel / Hex, Salbid +, Linosept and Berocin. CZ.

EROS - Serving health with the care it deserves

Eros: www.microeros.com

Brown & Burk was formed in the year 1979 by late Mr. G. C. Surana, Founder of Micro labs Ltd. This division was formed with an idea to train and develop people towards brand building.

This division caters to multi-specialties including neurologists, consulting physicians, General Physicians, Gynecologists, Pediatricians, Surgeons, Orthopedics, Dentists and ENT. Major therapy segment includes Stroke – Neuroprotection, Anti – Infective, Analgesic, Pain management, Anti Allergic, Neutraceuticals, Anti – Diarrhoeal etc.

The division’s annual turnover during its launch (1980 – 81) was close to Rs. 1 Crore with leading brands Eldoper and Pulmoxyl. Today, after 20 yrs the division makes an annual turnover of more than 100 Crores and monthly sales averaging higher than 9 Crores. B&B is 3rd largest division of Micro group and growing continuously with a double digit. In Karnataka BB ranks no. 1 in covered market. The division also has a strong control in UP, TN and Punjab markets. It has launched and developed many more brands.

The B&B stands for “Build People, Build Brands". We have regular training and development programs for employees, this helps them understand their brand better and co-relate them to commit on delivering better, thus decreasing attrition rate. Products are manufactured in-house and plants are internationally accredited.

Bactoclav is the leading brand for the division as well as the highest selling anti-biotic brand of Micro group. Pulmoxyl is highest prescribed brand in Amoxicillin group in Karnataka. Neurocetam and Clariwin are strong and are secondary within molecule. Neurocetam amongst Piracetam brands, Pulmocef, Eldoper of Loperamide, Loxon – T of Norfloxacin + Tinidazole and recently launched Gold are the best selling products of respective brands.

In future we plan to launch many more brands and to enhance the stroke basket.

B&B, commitment to healthcare continues.....

Carsyon, the Cardio-Diabetic Strategic Business Unit (SBU) of Micro Labs Limited was launched in the year 1994. The sole aim of this SBU was to fulfill the rapidly increasing demand for drugs for heart disease & diabetes. Thus, making Carsyon the very first focused Cardio-Diabetic SBU in the Indian Pharma Industry.

Since then Carsyon has been a trend setter in many of its strategic decisions. This division caters to cardiologists, diabetologists, general physicians, neurologists, nephrologists and general practioners. It launched its first brand Amlodipine + Atenolol (Amlong A), Losartan + Hydrochlorothiazide (Angizaar H), Amlodipine +Losartan (Amlozaar) & Gliclazide + Metformin (Dianorm-M) in India. Even after 14 years of its launch, Carsyon maintains its unwavering commitment to the Cardio-Diabetic fraternity through its ever increasing range of products, dedicated field force & strong customer relationship.

Carsyon participates in various international and national medical conferences and updates the industry and itself with latest developments. This division is often involved in lending academic support to students by providing books on cardio – diabetes and supports medical education.

It comes as no surprise to anyone that, With Carsyon's success, Micro Labs has been ranked among the top Cardio-Diabetic companies by IMS in the Indian Pharma Industry.

In the days to come Carsyon has plans to launch newer formulations which cater to the specific needs of the market. This division promises to ensure noteworthy performance to get even better as the days progress.

Carsyon: www.carsyon.com

Cardicare is specialty arm of Micro Labs Ltd. This wing was essentially started to expand horizons in Cardiology. Cardicare offers comprehensive product basket on emerging disease areas like Congestive Heart Failure, Hypertension, Dyslipidemias, Metabolic Syndrome and Arrhythmias. This division is based on promotion of science through innovation.

Cardicare’s strong equity in these therapy areas is unrelenting and fortified through the efforts of over 265 skilled field forces across the country. The distinctive space in our customer’s minds has been occupied by us, which is inscribed by 12th rank in the covered market and 24th in cardio vascular segment under cardiology sector as per IMS 2010.

The Cardicare Strategic Business Unit (SBU) of Micro Labs was launched in the year 2001. The solitary aim of this SBU is to cater to cardiovascular diseases. This makes Cardicare a focused Cardiology SBU in the Indian Pharma Industry.

The division’s pivotal brands are Hopace, Hopace – H, Arbitel, Astin. Other brands such as, Fibrovas, Nitrofix, Torsinex, metapro, Metapro – XL and Ezevas are productivity enhancers. Cardicare recently launched Cartinex and Oxprin brands.

Ever since its launch Cardicare has set new milestones. It maintains dense commitment to the Cardiology sector through its ever increasing range of products, dedicated field force & strong customer relationship.

Micro group has various therapeutic divisions catering to medical problems of human health. Similarly, Vet is another such division that deals with animal medical health. This division was launched in 1982 and is serving ANIMAL Healthcare sector for more than two decades.

Vet is a privileged medical provider to

• Avains or Poultry sector – layers, broilers, parents & grandparents,

• Large animal sector – Bovines, Caprines, Equinies

• Pet sector – Dogs, cats, etc

• Aqua sector – Prawn, Shrimp & Fish culture

• Recently providing to Emu Birds

Vet has wide range of products like animal feed supplement, antibiotic, anticoccidial, antihelminith, ectoparasitides, growth promoters, immunomodulators, vitamins & minerals supplements, enzymes, toxin binders, injectables and boluses.

Considering the fact that India is the 2nd largest producer of Egg & Meat and is the largest milk producer in the world, Vet is planning to cross Rs. 25 cr. by the year 2015 by introducing innovative products, increasing man power reach and strategic expansions.

This division exports to neighboring countries like Sri Lanka, Nepal, Bangaladesh and many other Asian countries.   

QUEST FOR BEST ANIMAL HEALTHCARE TROUGH QUALITY PRODUCTS